Breast Cancer Trial, Recruiting NCT06155305 Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Condition: Breast Cancer
Back to Breast Cancer

Breast Cancer Trial, Recruiting

NCT06155305
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are willing to take part and have signed a consent form agreeing to participate in the study.
  • You are a female between 18 and 70 years old.
  • You have been diagnosed with early-stage breast cancer (stages I to IIIA) that can be treated with surgery, your tumor is at least 2cm in size as shown on an MRI scan, and the cancer has not spread to other parts of the body. If there are multiple tumors, the largest one must be at least 2cm.
  • You are generally well enough to carry out daily activities with little or no limitation (confirm with trial site).
  • Your liver and kidney are working well enough, based on blood test results that fall within acceptable ranges (confirm with trial site).

Who may not be able to join:

  • You have already received treatment for your breast cancer before joining the trial.
  • Your breast cancer is at an advanced stage where surgery is not possible, or you have a type called inflammatory breast cancer.
  • You have cancer in both breasts.
  • You have multiple tumors spread across different areas (quadrants) of the same breast.
  • You are not considered a suitable candidate for chemotherapy given before surgery (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Jian Huang, 2 nd Affiliated Hospital, School of Medicine, Zhejiang University, China

Phone: +8657189713716

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
6 December 2023
Est. completion
1 December 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Correlation between drug sensitivity test results in patient-derived organoid models and clinical outcomes.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov